The Hereditary Cancer Unit of the Medical Oncology Department at Vall d’Hebron University Hospital and the Hereditary Cancer Genetics Group…
featured news
From April 17 to 22, the American Association for Cancer Research (AACR) Annual Meeting was held in San Diego. Researchers…
Once again, VHIO opened its doors to welcome more than 160 people who came to experience a morning of science…
Investigators from VHIO, which is part of the Vall Hebron Campus, publish the first study to address the impact of…
After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
The sports association “Els Veterans de Vilablareix” is a non-profit organisation that organises a wide range of sporting and leisure…
On April 9, the CRIS Cancer Foundation held the 2026 “CRIS Science Day” featuring the III CRIS International Symposium, focused…
Sponsored by F. Hoffmann-La Roche Ltd, in collaboration with Vall d’Hebron Institute of Oncology (VHIO), a first-in-human clinical trial was…
The Vall d’Hebron Institute of Oncology (VHIO) hosted the 3rd PragmaTIL Annual Meeting on March 26–27 in Barcelona, bringing together consortium partners to review the project’s…
The single arm phase II CALYPSO study evaluated the efficacy of MET inhibitor savolitinib combined with PD-L1 inhibitor durvalumab in…
